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Abstract
Background: Kinases downstream of growth factor receptors have been implicated in radioresistance and are,
therefore, attractive targets to improve radiotherapy outcome in head and neck squamous cell carcinoma
(HNSCC) patients.
Methods: An antibody-based array was used to quantify the expression levels of multiple phospho-kinases
involved in growth factor signaling in nine untreated or irradiated HNSCC lines. Radiosensitivity was assessed with
clonogenic cell survival assays and correlated with the expression levels of the phospho-kinases. Inhibitors of the
kinases that were associated with radiosensitivity were tested for their ability to increase radiosensitivity in the 3
most radioresistant HNSCC lines.
Results: The basal expression of phosphorylated Yes, Src and STAT5A, and the expression after radiotherapy of
phosphorylated AKT, MSK1/2, Src, Lyn, Fyn, Hck, and STAT6, were correlated with radiosensitivity in the panel of
HNSCC lines. In combination with radiotherapy, inhibitors of AKT, p38 and Src Family Kinases (SFK) were variably
able to reduce survival, whereas MEK1/2, STAT5 and STAT6 inhibition reduced survival in all cell lines. The combined
effect of radiotherapy and the kinase inhibitors on cell survival was mostly additive, although also supra-additive
effects were observed for AKT, MEK1/2, p38 and STAT5 inhibition.
Conclusions: Kinases of the AKT, MAPK, STAT and SFK pathways correlated with radiosensitivity in a panel of
HNSCC lines. Particularly inhibitors against MEK1/2, STAT5 and STAT6 were able to decrease survival in combination
with radiotherapy. Hence, inhibitors against these kinases have the potential to improve radiotherapy outcome in
HNSCC patients and further research is warranted to confirm this in vivo.
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Background
Radiotherapy is an integral part of the treatment of head
and neck squamous cell carcinoma (HNSCC) and is
successful in curing early-stage disease. However, the
majority of HNSCC patients presents with locoregionally
advanced disease for which cure rates remain relatively
poor [1]. Increasing insight in the biological features of
HNSCC tumors has resulted in the development of
new therapeutic agents that target molecules important
for survival after radiotherapy, including the Epidermal
Growth Factor Receptor (EGFR). Combining these new
agents with radiotherapy has already been successful in
the clinic as a phase III study by Bonner et al. [2] has
shown that cetuximab, a monoclonal antibody against
EGFR, improves survival in patients treated with radio-
therapy. However, despite this effect, a significant pro-
portion of the patients is resistant to EGFR-inhibition
and does not benefit from the addition of cetuximab.
One of the proposed resistance mechanisms is activation
of other growth factor receptors [3-6]. Different growth
factor receptors, such as EGFR, other members of the
ErbB family and MET, activate similar downstream
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pathways [7]. Due to this redundancy in signaling net-
works, cells overexpressing multiple growth factor re-
ceptors can sustain survival signaling when one of the
receptors is blocked. Therefore, it will be important to de-
termine the common downstream pathways that are re-
sponsible for cell survival after radiotherapy as they will
be more attractive targets to overcome radioresistance
than targeting one specific growth factor receptor.
Multiple kinase pathways downstream of growth factor
receptors have already been implicated in radioresis-
tance, including the RAS/RAF/ERK and the PI3-K/AKT
pathways [8-10]. To identify kinases that can be targeted
to increase radiosensitivity in HNSCC, it will be impor-
tant to explore multiple pathways. In this study, we used
an antibody-based array to quantify the expression levels
of multiple phosphorylated kinases in a panel of HNSCC
lines. The expression levels of these phospho-kinases
were correlated with radiosensitivity. Expression levels
were measured in untreated and irradiated cells as both
basal activity and activity induced by radiation of a ki-
nase could be important for cell survival after radiothe-
rapy. Inhibitors of the kinases that were associated with
radiosensitivity were tested for their ability to enhance
the radiotherapy effect in HNSCC. We identified several
kinase inhibitors that have the potential to increase ra-
diosensitivity of tumors and thereby improve the out-
come of HNSCC patients.
Materials and methods
Cell lines and chemicals
Nine human head and neck squamous cell carcinoma
cell lines (UT-SCC lines, generated by R.G., University
of Turku) were used in this study. The characteristics of
the cell lines are shown in Table 1. Cell lines were not
further authenticated or tested. Cells were cultured in
T75 culture flasks, under humidified conditions (37°C,
5% CO2), and passaged weekly or twice weekly in DMEM
containing 2 mM L-glutamine, 1% non-essential amino
acids, 20 mM Hepes, 10 units/ml penicillin, 10 units/ml
streptomycin, and 10% fetal bovine serum. The following
kinase inhibitors and concentrations were used (concen-
trations were chosen on the basis of effectiveness de-
scribed in the literature): Src Family Kinase inhibitor
dasatinib (100 nM, LC Laboratories, Woburn, MA,
USA) [11], AKT inhibitor MK-2206 (2 μM, Selleckchem,
Houston, TX, USA) [12], MEK1/2 inhibitor U0126
(10 μM, Merck Millipore, Billerica, MA, USA) [8],
p38 inhibitor SB203580 (10 μM, Selleckchem) [13],
STAT5 inhibitor 573108 (100 μM, Merck Millipore)
[14], and STAT6 inhibitor leflunomide (100 μM, Sigma,
St Louis, MO, USA) [15].
Human phospho-kinase antibody array
To determine levels of phospho-kinases at baseline and
after radiotherapy, cells were harvested after no treat-
ment or 1 h after a single dose of 4 Gy (320 KV, dose
rate 3.1 Gy/min, X-RAD, RPS Services Limited, Surrey,
UK). Cells were lysed using lysis buffer of the Human
phospho-kinase array kit (ARY003, Proteome Profiler™,
R&D Systems, Minneapolis, MN, USA) and protein was
quantitated using a standard Bradford absorbance assay.
The Human phospho-kinase array was performed ac-
cording the protocol of the manufacturer. In this array,
46 capture antibodies are spotted in duplicate on nitro-
cellulose membranes. The capture antibodies were di-
rected against the following antigens: AKT(S473), AKT
(T308), AMPKα1(T174), AMPKα2(T172), Chk-2(T68),
c-Jun(S63), CREB(S133), eNOS(S1177), ERK1/2(T202/
Y204), T185/Y187), FAK(Y397), Fgr(Y412), Fyn(Y420),
GSK-3α/β(S1/S9), Hck(Y411), HSP27(S78/S82), JNK pan
(T183/Y185, T221/Y223), Lck(Y394), Lyn(Y397), MEK1/
2(S218/S222, S222/226), MSK1/2(S376/S360), p27(T157),
p27(T198), p38α(T180/Y182), p53(S15), p53(S46), p53
(S392), p70 S6 kinase (T229), p70 S6 Kinase (T389), p70
S6 kinase (T421/S424), Paxillin(Y118), PLCγ-1(Y783),
Pyk2(Y402), RSK1/2(S221), RSK1/2/3(S380), Src(Y419),
Table 1 Characteristics of UT-SCC cell lines
Cell line TNM* Primary tumor location Type of lesion Grade SF4 ± SEM
UT-SCC5 T1N1M0 Tongue Primary 2 0.42 ± 0.03
UT-SCC8 T2N0M0 Supraglottic larynx Primary 1 0.22 ± 0.02
UT-SCC15 T1N0M0 Tongue Recurrence 1 0.31 ± 0.02
UT-SCC19A T4N0M0 Glottic larynx Primary 2 0.19 ± 0.02
UT-SCC24A T2N0M0 Tongue Primary 2 0.40 ± 0.02
UT-SCC29 T2N0M0 Glottic larynx Primary 1 0.23 ± 0.01
UT-SCC38 T2N0M0 Glottic larynx Primary 2 0.23 ± 0.03
UT-SCC40 T3N0M0 Tongue Primary 1 0.33 ± 0.02
UT-SCC45 T3N1M0 Floor of mouth Primary 3 0.28 ± 0.03
*TNM status of primary tumors according to the International Union against Cancer (1997).
Note: Grade: 1, well differentiated; 2, moderately differentiated; 3, poorly differentiated.
SF4, Surviving fraction after 4 Gy; SEM, Standard error of the mean.
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STAT1(Y701), STAT2(Y689), STAT3(Y705), STAT4
(Y693), STAT5a(Y699), STAT5a/b(Y699), STAT5b(Y699),
STAT6(Y641), TOR(S2448), Yes(Y426) and β-catenin. In
short, cell lysates were incubated with the membrane
overnight. Thereafter, the membranes were incubated
with a cocktail of biotinylated detection antibodies and
streptavidin-HRP. Finally, proteins were detected using an
ECL chemiluminescent system. To quantify expression
levels, the integrated optical density (IOD) of each spot
was measured using ImageJ software (NIH, Bethesda, MD,
USA). IOD values were corrected for background signal
and to compare different membranes levels were normal-
ized to those of the positive controls on each membrane.
Both the absolute expression levels after radiotherapy as
well as the relative levels (expression after radiotherapy/
expression in control) after radiotherapy were quantified.
Radiosensitivity: Clonogenic cell survival assays
Cells were irradiated with graded doses (2, 4, or 8 Gy) at
room temperature. After 1.5-3 weeks, depending on the
growth speed of the cell line, cells were stained with
0.5% crystal violet and colonies with more than 50 cells
were counted. Clonogenic survival curves were fitted
using the linear quadratic model and the surviving frac-
tion after 4 Gy (SF4) was calculated using the α and β
values obtained from the curve.
Kinase inhibition: Clonogenic cell survival assays &
western blot analyses
For clonogenic cell survival assays, cells were incubated
with the kinase inhibitor for 16 h and then irradiated
with 4 Gy. Thereafter, cells were treated with the kinase
inhibitor for 72 h (total 88 h of treatment) and subse-
quently cells were incubated in drug free medium. After
1.5-3 weeks, cells were stained with crystal violet and
colonies were counted. Survival fraction after combined
treatment with 4 Gy and the kinase inhibitor was calcu-
lated by correcting for plating efficiency of the untreated
control or by correcting for plating efficiency of cells
treated with the inhibitor alone.
For western blot analyses, cells were treated with the
inhibitor for 16 h followed by irradiation with 4 Gy and
harvested 4 h after radiotherapy or 20 h after kinase
treatment. Cells were lysed in RIPA buffer and protein
was quantitated using a standard Bradford absorbance
assay. Proteins (25 μg per lane) were separated by SDS-
PAGE and blotted onto PVDF membrane. Membranes
were incubated with the appropriate primary antibodies
followed by incubation with HRP-conjugated antibodies.
Finally, proteins were detected using chemilumines-
cence. Antibodies against the following antigens were
used: p-p38(T180/Y182), pMEK1/2(S217/221), pMSK1
(S376), pSFK(Y416), pSTAT6(Y641), pSTAT5(Y694),
pAKT(S473), pERK1/2(T202/Y204), and HRP-conjugated
goat-anti-rabbit IgG were purchased from Cell Signaling
Technology (Beverly, MA, USA), HRP-conjugated goat-
anti-mouse IgG was purchased from Santa Cruz Bio-
technology (Santa Cruz, CA, USA), and α-tubulin was
obtained from Calbiochem (San Diego, CA, USA).
Statistics
Correlations between expression levels of phospho-
kinases (absolute levels in control, and both absolute
levels and relative levels after radiotherapy) and SF4
values were assessed using the Spearman correlation
test. To determine additive effects of combined treatment,
differences between survival after 4 Gy and 4 Gy + inhibi-
tor were tested for significance using the Mann–Whitney
test. To determine supra-additive effects of combined
treatment, differences between survival after 4 Gy and
4 Gy + inhibitor corrected for effect of inhibitor alone
were tested for significance using the Mann–Whitney test.
Tests were performed using Prism (GraphPad Software,
Inc., LA Jolla, CA, USA) or SPSS (SPSS, Chicago, IL,
USA). P-values ≤0.05 were considered significant.
Results
Expression of phospho-kinases correlated with radiosensi-
tivity in a panel of HNSCC cell lines
The radiosensitivity of 9 HNSCC cell lines was assessed
with clonogenic survival assays after 0, 2, 4 and 8 Gy.
Using the linear quadratic model, the surviving fraction
after 4 Gy (SF4) was calculated for each cell line
(Table 1). To determine which kinases are important for
cell survival after radiotherapy in HNSCC, we quantified
the expression of a panel of phospho-kinases using an
antibody-based array in untreated and irradiated cells
(Figure 1). The effect of radiotherapy on most phospho-
kinases varied widely among cell lines, only the ex-
pression of p-Chk2 was increased in all cell lines after
radiotherapy (Figure 1). The expression levels of mul-
tiple phospho-kinases were found to be significantly cor-
related with radiosensitivity (p-values ≤ 0.05 of spearman
correlation test, Table 2). Only positive correlations were
observed, indicating that higher levels of expression ba-
sally or after radiation for each of these proteins correlated
with increasing radioresistance. For some phosphorylated
kinases the basal expression level was correlated with ra-
diosensitivity (Yes and STAT5A), whereas for others the
expression level after radiotherapy (AKT, MSK1/2, Lyn,
Fyn, Hck, STAT6). For phosphorylated Src both the basal
expression level as well as the expression level after radio-
therapy were correlated with radiosensitivity.
Radiosensitizing effect of kinase inhibitors
The significant correlation between the expression levels
of these phosphorylated kinases and radiosensitivity indi-
cates that the activity of these kinases might be important
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for cell survival after radiotherapy. Indeed, AKT and Src
have been implicated in resistance to radiotherapy in
HNSCC before [9,11] and were also found to be correla-
ted with radiosensitivity in this study. Hence, these kinases
might represent new targets to increase radiosensitivity in
HNSCC. To test this hypothesis, clonogenic survival as-
says were performed with inhibitors against these various
kinases in combination with radiotherapy in 3 UT-SCC
lines with the highest SF4 values i.e. the most radioresistant
tumor cell lines; UT-SCC5, 24A and 40 (Figure 2A-F).
MK-2206, 573108 STAT5 inhibitor, and leflunomide were
used to inhibit AKT, STAT5 and STAT6, respectively.
Dasatinib was used to inhibit the kinases of the Src Family
Kinase (SFK), which include Src, Yes, Lyn, Fyn and Hck.
MSK1/2 can be activated via both the MEK/ERK pathway
as well as the p38 pathway [16]. Therefore, both U0126
and SB203580 were used to inhibit MEK1/2 and p38, re-
spectively, and thereby inhibit downstream MSK1/2. Next
to the clonogenic survival assays, western blot analyses
were performed on cells treated with the inhibitor and/or
radiotherapy to determine the effects of the inhibitors on
the phosphorylated kinases (Figure 3A-F).
As shown in Figure 2A, AKT inhibition significantly
decreased survival after 4 Gy in UT-SCC24A (p = 0.030)
and UT-SCC40 (p = 0.002). This effect was supra-
additive in UT-SCC40 (p = 0.002). In all three cell lines
AKT inhibition with or without radiotherapy clearly de-
creased pAKT levels (Figure 3A). SFK inhibition only
decreased survival after 4 Gy in UT-SCC24A (p = 0.002),
and this was not a synergistic effect (Figure 2B). Western
blot analyses also showed only a clear decrease in pSFK
levels in UT-SCC24A cells (Figure 3B). MEK inhibition
significantly decreased survival after 4 Gy in all cell lines
(p < 0.001), which was supra-additive in UT-SCC24A
(p = 0.004) (Figure 2C). MEK inhibition increased
pMEK1/2 levels in all cell lines (Figure 3C). In contrast,
downstream pERK1/2 levels were decreased after MEK
inhibition, indicating that the kinase activity of MEK1/2
was decreased despite a higher level of phosphorylated
MEK1/2. However, this inhibition of ERK1/2 did only
lead to reduced pMSK1 levels in UT-SCC40 (Figure 3C).
Inhibition of p38 in combination with radiotherapy also
led to a reduction of survival in UT-SCC24A (p = 0.002),
which was a supra-additive effect (p = 0.002) (Figure 2D).
Similar to what was seen using the MEK inhibitor, p38
inhibition did not lead to reduced p-p38 levels; rather
p-p38 levels were increased in UT-SCC24A that showed
a synergistic effect of p38 inhibition and radiotherapy
(Figure 3D). However, no decrease in downstream
pMSK1 levels were seen in any of the three cell lines
after p38 inhibition indicating that the effect of p38 in-
hibition was not related to effects on MSK1 activity.
As shown in Figures 2E and 2F, both STAT5 and
STAT6 inhibition led to a significantly decreased survival
after 4 Gy in all cell lines (p < 0.01 and p < 0.05). For
STAT6 inhibition this was only an additive effect, while
STAT5 inhibition and 4 Gy had a supra-additive ef-
fect on cell survival in UT-SCC40. Both pSTAT5 and
pSTAT6 levels were low and difficult to detect on
western blot. Reduction of pSTAT5 was observed in
UT-SCC40 and of pSTAT6 in UT-SCC5 and UT-SCC40
(Figure 3E,F).
Table 2 Phospho-kinases correlated with radiosensitivity
in HNSCC
Phospho-kinase Condition Spearman
correlation
coefficient
P-value
Src(Y419) Expression in control 0.67 0.049
Expression after RT 0.75 0.019
STAT5A(Y699) Expression in control 0.70 0.036
Yes(Y426) Expression in control 0.67 0.050
AKT(S437) Relative expression after RT 0.67 0.050
MSK1/2(S376/S360) Expression after RT 0.67 0.050
Lyn(Y397) Expression after RT 0.70 0.036
Fyn(Y420) Expression after RT 0.70 0.036
Hck(Y411) Expression after RT 0.72 0.030
STAT6(Y641) Expression after RT 0.67 0.050
RT: 4 Gy of radiotherapy.
Expression in control or after RT: absolute expression level in control or 1 h
after RT.
Relative expression after RT: expression after radiotherapy divided by
expression in control.
Figure 1 Phospho-kinase array in control and irradiated
UT-SCC24A cells. Example of phospho-kinase array in untreated
UT-SCC24A cells and 1 h after 4 Gy irradiation. Cell lysates were
incubated with membranes containing capture antibodies (spotted
in duplicate) against 46 kinase phosphorylation sites. Thereafter, the
membranes were incubated with a cocktail of biotinylated detection
antibodies and streptavidin-HRP. Proteins were detected using
chemiluminescence and expression levels were quantified by
measuring the integrated optical density (IOD) of each spot.
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Discussion
In this study, an antibody-based array was used to de-
termine which activated kinases involved in growth fac-
tor signaling were correlated with radiosensitivity in
HNSCC. This screen resulted in multiple kinases of dif-
ferent pathways, which could be potential targets to in-
crease radiosensitivity. Pathways known to be associated
with radiosensitivity were found, including the RAS/
Figure 2 Effects of kinase inhibitors on survival after radiotherapy. UT-SCC5, 24A and 40 cell lines were treated with the inhibitor overnight
(16 h), irradiated with 4 Gy and changed to drug free medium 72 h after irradiation. Survival was assessed via colony counting. A) AKT inhibitor:
MK-2206 (2 μM), B) SFK inhibitor: dasatinib (100 nM), C) MEK1/2 inhibitor: U0126 (10 μM), D) p38 inhibitor: SB203580 (10 μM), E) STAT5 inhibitor:
573108 (100 μM), F) STAT6 inhibitor: leflunomide (100 μM). Survival fraction shown in graph was not corrected for the effect of the inhibitor alone.
Differences between survival after 4 Gy and 4 Gy + inhibitor (additive effect, first asterisks) or 4 Gy and 4 Gy + inhibitor corrected for effect of
inhibitor alone (supra-additive effect, second asterisks) were tested for significance using Mann–Whitney tests. *: p < 0.05, **: p < 0.01. Error bars
represent SD.
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RAF/ERK and the PI3-K/AKT pathways [8-10], valida-
ting our approach. In addition, kinases not known to be
involved in radiosensitivity were identified, including
STAT5 and STAT6. Moreover, inhibitors of these kinases
were able to decrease survival after radiotherapy, par-
ticularly inhibitors against MEK1/2, STAT5 and STAT6.
Hence, these kinases represent potential new targets to
improve outcome after radiotherapy in HNSCC patients.
The PI3-K/AKT pathway has been shown to regulate
important cell survival mechanisms that induce radiore-
sistance, including DNA repair and proliferation [9].
Hence, inhibition of this pathway has been shown to be
a major mechanism for the radiosensitizing effect of
EGFR-inhibitors [17,18] and this is strengthened by the
observation that activation of AKT has been implicated
in resistance to EGFR-inhibition [19]. Here, we show
Figure 3 Western blot analysis of phospho-kinases after treatment with inhibitor and/or radiotherapy. UT-SCC5, 24A and 40 cells were
incubated with the inhibitor overnight (16 h), irradiated with 4 Gy and harvested 4 h after radiotherapy treatment or 20 h after kinase treatment.
A) AKT inhibitor: MK-2206 (2 μM), B) SFK inhibitor: dasatinib (100 nM), C) MEK1/2 inhibitor: U0126 (10 μM), D) p38 inhibitor: SB203580 (10 μM),
E) STAT5 inhibitor: 573108 (100 μM), F) STAT6 inhibitor: leflunomide (100 μM). α-tubulin was used as loading control.
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that pAKT inhibition via MK-2206 can decrease survival
after radiotherapy. This effect was supra-additive in one
cell line, indicating that pAKT inhibition specifically
decreased survival after radiotherapy in this cell line.
However, pAKT inhibition did not decrease survival in
all cell lines we tested, despite consistently good inhib-
ition of pAKT levels (Figure 3A). Several mechanisms
could explain this difference in radiosensitizing effect of
MK-2206 between cell lines. Firstly, the importance of
AKT activity for cell survival could differ between cell
lines; for example also other kinases were highly ex-
pressed in resistant line UT-SCC5, and, therefore, inhib-
ition of pAKT would not be deleterious for all cell lines.
Moreover, numerous feedback systems are present be-
tween growth factor receptors and their downstream
pathways, whereby inhibition of one kinase can lead to
activation of receptors and consequently activation of
other downstream pathways [20,21]. These feedback me-
chanisms can greatly impact the sensitivity of cells to
kinase inhibitors. In addition, these mechanisms are
likely differentially active between cell lines as they will
be dependent on which receptors and kinases are (over)
expressed or preferentially activated in a cell.
Several members of the family of Src kinases were also
found to be correlated with radiosensitivity. SFKs have
been shown to be involved in pathways that control cell
division and survival [22,23] and Src has been implicated
in AKT activation after radiotherapy [24]. However,
dasatinib was only able to reduce survival after ra-
diotherapy in UT-SCC24A cells in an additive way. This
is in contrast with a recent study by Raju et al. [11],
which showed that dasatinib enhances radiosensitivity in
HNSCC cells via inhibition of radiation-induced DNA
repair. A possible reason for this discrepancy is that due
to differential sensitivity our panel of 3 cell lines was too
small to detect the radiosensitizing effect of dasatinib.
Namely, in the study of Raju et al. only 2 out of 6 cancer
lines showed radiosensitization by dasatinib [11]. None-
theless, these data together suggest that dasatinib can
radiosensitize tumors, but that dasatinib is probably not
effective in the majority of HNSCC patients.
In contrast to dasatinib, inhibition of MEK1/2 did
result in decreased survival after radiotherapy in all
cell lines, with a supra-additive effect in UT-SCC24A.
MEK1/2 and its downstream kinases ERK1/2 have been
implicated in radioresistance in HNSCC before, although
the effect of pathway inhibition on radiosensitivity is in-
consistent [8,25]. In this study, MEK1/2 inhibition was
used to inhibit downstream phosphorylation of MSK1/2,
which was correlated with radiosensitivity. Though clear
inhibition of pERK1/2 was detected in all cell lines,
pMSK1 was only decreased in UT-SCC40, which only
showed an additive effect of MEK inhibition. Hence,
these data suggest that the radiosensitizing effect of
MEK inhibition is not regulated via MSK. Specific inhib-
ition of MSK will be necessary to further investigate the
role of MSK in radioresistance in HNSCC. Interestingly,
the cell line that showed synergism between MEK inhi-
bition and radiotherapy, also showed a synergistic effect
of p38 inhibition. Also with this inhibitor no decrease
of pMSK1 levels was observed. MEK and p38 both
belong to the family of mitogen-activated protein ki-
nases (MAPKs) [16]. Therefore, MEK and p38 may
activate another common pathway that is important
for survival after radiotherapy in UT-SCC24A cells,
for example both MEK and p38 can activate MNK1
and thereby regulate mRNA translation [16].
Surprisingly, increased pMEK1/2 levels were observed
in all cell lines after MEK inhibition (Figure 3C), and
also p-p38 was increased by p38 inhibition in the cell
line that showed decreased survival after radiotherapy
(UT-SCC24A, Figure 3D). Upregulation of pMEK1/2
after MEK inhibition has also been observed by Turke
et al. [21] and they attributed it to a negative feedback
mechanism that activates an upstream signaling mol-
ecule. Indeed, we did observe decreased pERK1/2 levels
indicating that MEK activity was decreased by the in-
hibitor despite increased pMEK1/2 levels. Accordingly,
increased p-p38 levels after p38 inhibition in the sen-
sitive cell line might indicate effective inhibition of
p38 and its downstream pathways instead of increased
activity of p38.
Members of the STAT family have been shown to be
activated in epithelial tumors, including HNSCC, and
are known to induce the transcription of genes involved
in cell survival, proliferation and angiogenesis [26]. Acti-
vation of STAT5 has also been shown to contribute to
tumor growth and resistance to cisplatin and EGFR-
inhibition in HNSCC cell lines [27]. However, it has not
been previously described that STAT5 and STAT6 cor-
relate with radiosensitivity as we find in our study. An-
other member of the STAT family, STAT3, has been
shown to be involved in resistance to radiotherapy
[28]. Hence, our results indicate that also other STAT
members play an important role in radiosensitivity in
HNSCC. This is also indicated by a study of Lesterhuis
et al. [29], who observed a trend toward a shorter pro-
gression-free survival for STAT6 expressing tumors in a
cohort of HNSCC patients treated with radiotherapy
only. More importantly, inhibition of STAT5 and STAT6
consistently decreased survival after radiation in all cell
lines. Although these effects on survival were mostly
additive, these data do suggest that inhibition of STAT5
and STAT6 has the potential to improve outcome after
radiotherapy in a large proportion of HNSCC patients.
However, our results have to be interpreted with caution.
The effects of the inhibitors on pSTAT5 and pSTAT6
levels were small, although as we demonstrated for other
Stegeman et al. Molecular Cancer 2013, 12:133 Page 7 of 9
http://www.molecular-cancer.com/content/12/1/133
kinases (MEK, p38), this does not necessarily reflect the
activity of these kinases. Furthermore, leflunomide is not
a very specific STAT6 inhibitor and we cannot exclude
the possibility that the effect of leflunomide on cell sur-
vival is independent of STAT6 inhibition.
The specificity of the used inhibitors might be con-
firmed by performing knockdown experiments with
siRNAs against the kinases identified in these experi-
ments. However, also siRNAs are known to be prone to
off-target effects and transfection of cells can induce
stress responses that could have important consequences
for the response to radiation of these cells. In addition,
although specificity is an important issue, more import-
ant is that we show that multiple clinical available inhib-
itors have the potential to improve outcome after
radiotherapy in HNSCC patients.
Altogether, mostly additive effects of the kinase inhi-
bitors were observed in this study indicating that these
inhibitors decreased tumor cell survival in general and
not specifically after radiotherapy. Although a synergistic
effect of a kinase inhibitor and radiotherapy would be
preferred, combination therapies that result in reduced
survival due to additive effects could still offer the prom-
ise of improving patient outcome after radiotherapy in
the clinic. Especially when these additive effects occur in
a large proportion of the patients. Recurrences after radio-
therapy often occur from a few surviving clonogenic cells
and this suggests that additional kill of clonogenic cells by
a kinase inhibitor would contribute to local tumor control
[30]. Further research will be necessary to assess the effi-
cacy of these inhibitors to improve outcome after radio-
therapy in vivo and ultimately in patients. Some of the
concentrations used in our experiments to inhibit kinases
were in the micromolar range and it can be questioned
whether effective inhibitor concentrations will be obtai-
nable in vivo and, hence, whether our findings can be
directly extrapolated to the clinic. Our own group has
already shown that combining dasatinib with radiotherapy
results in a significant effect on growth delay in HNSCC
xenografts, while either treatment alone has no effect on
tumor growth [31]. In addition, clinical studies performed
with dasatinib and MK-2206, have already shown to be
able to effectively inhibit pSrc and pAKT, respectively
[32,33]. Nonetheless, it will still need to be determined
whether these inhibitors are also able to improve outcome
after radiotherapy in the clinic. Lastly, the challenge for
the future will be to determine which kinase pathway(s)
are crucial for tumor cell survival in an individual patient
and, hence, to determine which kinase inhibitor(s) will
most likely be effective in that patient.
Conclusion
Kinases of the PI3-K/AKT, MAPK, STAT and SFK path-
ways were shown to be correlated with radiosensitivity
in HNSCC cells. Inhibitors of these kinases were able
to decrease survival after radiotherapy, in particular
MEK1/2, STAT5 and STAT6 inhibitors. Hence, kinase
inhibitors have the potential to increase radiosensitivity of
tumors and thereby improve the outcome of HNSCC
patients after radiotherapy. However, as with inhibi-
tors against growth factor receptors, tumor cell lines
display differential sensitivity. Further research is war-
ranted to increase insight in mechanisms involved in
resistance to these kinase inhibitors and how they can
be counteracted to increase the efficacy of these ki-
nase inhibitors. Secondly, kinase inhibition should be
tailored to the preferential signaling pathway activa-
tion of individual tumors.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
HS designed and coordinated the project, performed the kinase arrays and
drafted the manuscript. JHK, AJK, and JB obtained funding for this project
and participated in its design and coordination, and drafted the manuscript.
PNS helped with the statistical analyses and interpretation of the data and
revised the manuscript. DLW and MI participated in the design and
interpretation of the data. WJP and MMV designed and performed the cell
culture experiments and performed the western blot analyses. RG provided
the cell lines and revised the manuscript. All authors read and approved the
final manuscript.
Acknowledgements
This project was financially supported by the Dutch Cancer Society, grant
number 2008–4000, and, in part by the Clinical and Translational Science
Award (CTSA) program, through the National Center for Advancing
Translational Sciences (NCATS), grant 9U54TR000021 (DLW). The content is
solely the responsibility of the authors and does not necessarily represent
the official views of the NIH.
Author details
1Department of Radiation Oncology, Radboud University Nijmegen Medical
Centre, PO Box 9101, 6500, HB Nijmegen, The Netherlands. 2Department of
Human Oncology, University of Wisconsin School of Medicine and Public
Health, 1111 Highland Ave, Madison 53705, WI, USA. 3Department of
Otorhinolaryngology-Head and Neck Surgery and Department of Medical
Biochemistry, Turku University Hospital and University of Turku, PO Box 52,
FI-20521 Turku, Finland.
Received: 10 July 2013 Accepted: 31 October 2013
Published: 5 November 2013
References
1. Harari PM, Ritter MA, Petereit DG, Mehta MP: Chemoradiation for upper
aerodigestive tract cancer: balancing evidence from clinical trials with
individual patient recommendations. Curr Probl Cancer 2004, 28:7–40.
2. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R,
Raben D, Jassem J, et al: Radiotherapy plus cetuximab for squamous-cell
carcinoma of the head and neck. N Engl J Med 2006, 354:567–578.
3. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA,
Benavente S, Gondi V, Hsu KT, Harari PM: Mechanisms of acquired
resistance to cetuximab: role of HER (ErbB) family members. Oncogene
2008, 27:3944–3956.
4. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K,
Wong A, Lee CV, Stawicki S, et al: A two-in-one antibody against HER3
and EGFR has superior inhibitory activity compared with monospecific
antibodies. Cancer Cell 2011, 20:472–486.
5. Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM: Dual
blockade of EGFR and c-Met abrogates redundant signaling and
Stegeman et al. Molecular Cancer 2013, 12:133 Page 8 of 9
http://www.molecular-cancer.com/content/12/1/133
proliferation in head and neck carcinoma cells. Clin Cancer Res 2011,
17:4425–4438.
6. Stegeman H, Kaanders JH, van der Kogel AJ, Iida M, Wheeler DL, Span PN,
Bussink J: Predictive value of hypoxia, proliferation and tyrosine kinase
receptors for EGFR-inhibition and radiotherapy sensitivity in head and
neck cancer models. Radiother Oncol 2013, 106:383–389.
7. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A,
Nardone J, Innocenti G, Wetzel R, et al: Signaling networks assembled by
oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008, 105:692–697.
8. Affolter A, Fruth K, Brochhausen C, Schmidtmann I, Mann WJ, Brieger J:
Activation of mitogen-activated protein kinase extracellular signal-related
kinase in head and neck squamous cell carcinomas after irradiation as part
of a rescue mechanism. Head Neck 2011, 33:1448–1457.
9. Bussink J, van der Kogel AJ, Kaanders JH: Activation of the PI3-K/AKT
pathway and implications for radioresistance mechanisms in head and
neck cancer. Lancet Oncol 2008, 9:288–296.
10. Meyn RE, Munshi A, Haymach JV, Milas L, Ang KK: Receptor signaling as a
regulatory mechanism of DNA repair. Radiother Oncol 2009, 92:316–322.
11. Raju U, Riesterer O, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM,
Glisson B, Milas L, Ang KK: Dasatinib, a multi-kinase inhibitor increased
radiation sensitivity by interfering with nuclear localization of epidermal
growth factor receptor and by blocking DNA repair pathways. Radiother
Oncol 2012, 105:241–249.
12. Stegeman H, Kaanders JH, Wheeler DL, van der Kogel AJ, Verheijen MM,
Waaijer SJ, Iida M, Grenman R, Span PN, Bussink J: Activation of AKT by
hypoxia: a potential target for hypoxic tumors of the head and neck.
BMC Cancer 2012, 12:463.
13. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of
action of some commonly used protein kinase inhibitors. Biochem J 2000,
351:95–105.
14. Marwarha G, Prasanthi JR, Schommer J, Dasari B, Ghribi O: Molecular
interplay between leptin, insulin-like growth factor-1, and beta-amyloid
in organotypic slices from rabbit hippocampus. Mol Neurodegener 2011,
6:41.
15. Moynihan B, Tolloczko B, Michoud MC, Tamaoka M, Ferraro P, Martin JG:
MAP kinases mediate interleukin-13 effects on calcium signaling in
human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol
2008, 295:L171–L177.
16. Roux PP, Blenis J: ERK and p38 MAPK-activated protein kinases: a family
of protein kinases with diverse biological functions. Microbiol Mol Biol Rev
2004, 68:320–344.
17. Toulany M, Kasten-Pisula U, Brammer I, Wang S, Chen J, Dittmann K,
Baumann M, Dikomey E, Rodemann HP: Blockage of epidermal growth
factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases
radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting
DNA repair. Clin Cancer Res 2006, 12:4119–4126.
18. Kang KB, Zhu C, Wong YL, Gao Q, Ty A, Wong MC: Gefitinib radiosensitizes
stem-like glioma cells: inhibition of epidermal growth factor receptor-
Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand
break repair. Int J Radiat Oncol Biol Phys 2012, 83:e43–e52.
19. Wheeler DL, Dunn EF, Harari PM: Understanding resistance to EGFR
inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010,
7:493–507.
20. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O,
Serra V, Majumder PK, Baselga J, Rosen N: AKT inhibition relieves feedback
suppression of receptor tyrosine kinase expression and activity. Cancer Cell
2011, 19:58–71.
21. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA:
MEK inhibition leads to PI3K/AKT activation by relieving a negative
feedback on ERBB receptors. Cancer Res 2012, 72:3228–3237.
22. Summy JM, Gallick GE: Src family kinases in tumor progression and
metastasis. Cancer Metastasis Rev 2003, 22:337–358.
23. Yeatman TJ: A renaissance for SRC. Nat Rev Cancer 2004, 4:470–480.
24. Kim MJ, Byun JY, Yun CH, Park IC, Lee KH, Lee SJ: c-Src-p38 mitogen-
activated protein kinase signaling is required for Akt activation in
response to ionizing radiation. Mol Cancer Res 2008, 6:1872–1880.
25. Bonner JA, Vroman BT, Christianson TJ, Karnitz LM: Ionizing radiation-
induced MEK and Erk activation does not enhance survival of irradiated
human squamous carcinoma cells. Int J Radiat Oncol Biol Phys 1998,
42:921–925.
26. Lai SY, Johnson FM: Defining the role of the JAK-STAT pathway in head
and neck and thoracic malignancies: implications for future therapeutic
approaches. Drug Resist Updat 2010, 13:67–78.
27. Koppikar P, Lui VW, Man D, Xi S, Chai RL, Nelson E, Tobey AB, Grandis JR:
Constitutive activation of signal transducer and activator of transcription
5 contributes to tumor growth, epithelial-mesenchymal transition, and
resistance to epidermal growth factor receptor targeting. Clin Cancer Res
2008, 14:7682–7690.
28. Bonner JA, Trummell HQ, Willey CD, Plants BA, Raisch KP: Inhibition of
STAT-3 results in radiosensitization of human squamous cell carcinoma.
Radiother Oncol 2009, 92:339–344.
29. Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S,
Schreibelt G, de Boer A, van Herpen CM, Kaanders JH, et al: Platinum-based
drugs disrupt STAT6-mediated suppression of immune responses against
cancer in humans and mice. J Clin Invest 2011, 121:3100–3108.
30. Baumann M, Krause M, Dikomey E, Dittmann K, Dorr W, Kasten-Pisula U,
Rodemann HP: EGFR-targeted anti-cancer drugs in radiotherapy:
preclinical evaluation of mechanisms. Radiother Oncol 2007, 83:238–248.
31. Stegeman H, Span PN, Rijken PF, Cockx SC, Wheeler DL, Iida M, van der
Kogel AJ, Kaanders JH, Bussink J: Dasatinib Inhibits DNA Repair after
Radiotherapy Specifically in pSFK-Expressing Tumor Areas in Head and
Neck Xenograft Tumors. Transl Oncol 2013, 6:413–419.
32. Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A,
Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA: Phase 2
study of dasatinib in the treatment of head and neck squamous cell
carcinoma. Cancer 2011, 117:2112–2119.
33. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD,
Delgado L, Taylor A, Lupinacci L, et al: First-in-man clinical trial of the
oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
J Clin Oncol 2011, 29:4688–4695.
doi:10.1186/1476-4598-12-133
Cite this article as: Stegeman et al.: Combining radiotherapy with
MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck
cancer lines. Molecular Cancer 2013 12:133.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Stegeman et al. Molecular Cancer 2013, 12:133 Page 9 of 9
http://www.molecular-cancer.com/content/12/1/133
